Barclays analyst Adam Seiden maintains AECOM (NYSE:ACM) with a Overweight and raises the price target from $82 to $85.
Morgan Stanley Upgrades Fulcrum Therapeutics to Overweight, Announces $34 Price Target
Morgan Stanley analyst Matthew Harrison upgrades Fulcrum Therapeutics (NASDAQ:FULC) from Equal-Weight to Overweight and announces $34 price target.